Open AccessCase Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19
Author(s) -
Melissa Barreto Falcão,
Luciano Pamplona de Góes Cavalcanti,
Nivaldo Menezes Filgueiras Filho,
Carlos Alexandre Antunes de Brito
Publication year - 2020
Publication title -
american journal of tropical medicine and hygiene
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.015
H-Index - 151
eISSN - 1476-1645
pISSN - 0002-9637
DOI - 10.4269/ajtmh.20-0276
Subject(s) - hydroxychloroquine , covid-19 , medicine , adverse effect , pandemic , liver function , coronavirus , gastroenterology , disease , virology , infectious disease (medical specialty) , outbreak
Hydroxychloroquine (HCQ) has been used for the treatment of novel coronavirus disease (COVID-19) cases. However, evidence of efficacy remains limited, and adverse events can be associated with its use. Here, we report a case of a patient with severe COVID-19 who, after being administered HCQ, exhibited a 10-fold increase in serum levels of transaminases, followed by a rapid decrease after HCQ was withdrawn. Considering the significantly increased use of HCQ during the COVID-19 pandemic, this case alerts us to the potential for HCQ to be associated with hepatotoxicity and the need to monitor liver function during HCQ therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom